Metabolic Biophysics and Applied Pharmacology Laboratory, Faculty of Medicine Ibn El Jazzar Sousse, Sousse University, Tunisia; University of Sousse, Faculty of Medicine Ibn El Jazzar, Sousse, Tunisia.
Neurology Department, Sahloul Teaching Hospital, Sousse, Tunisia; University of Sousse, Faculty of Medicine Ibn El Jazzar, Sousse, Tunisia.
Parkinsonism Relat Disord. 2021 Oct;91:23-27. doi: 10.1016/j.parkreldis.2021.08.013. Epub 2021 Aug 25.
The effect of Origanum majorana tea consumption on motor and non-motor symptoms was investigated in patients with idiopathic Parkinson's disease, measured by validated tools.
Sixty patients with idiopathic Parkinson's disease and under conventional medication were enrolled voluntarily in the study. All participants were randomized on double-blind to placebo or Origanum majorana. Clinical assessment with validated tools (UPDRSIII, NMSS, and BDI) was done before Origanum majorana or placebo consumption (Day 0) and at the end of the experiment (Day 30).
The treatment groups were similar at baseline on demographic and clinical variables. During the course of study, nine participants withdrew for reasons of noncompliance and inability to follow-up. Fifty-one participants completed the study. Upon completion of 30 days of treatment, Origanum majorana tea consumption did not decrease the UPDRSIII score ([UPDRSIII D0 = 18.76 ± 8.58, D30 = 16.52 ± 7.96, p = 0.069) at the p value was 0.07. However, a statistically significant improvement was noted in NMSS and BDI scores (p < 0.0001 and p < 0.0001, respectively). Assessment of the UPDRSIII, NMSS and BDI scores of the patients did not reflect any improvement with placebo. No side effect was detected during the study CONCLUSION: These findings show improvement of depressive and non-motor signs in patients with Parkinson's disease in the group that consumed Origanum majorana tea in combination with conventional therapy. Improvement of motor signs may need an extended treatment period. However, more research with a large number of participants and lasting longer than 1 month is needed to argue these findings.
本研究旨在通过验证工具评估迷迭香茶对特发性帕金森病患者运动和非运动症状的影响。
本研究共纳入 60 例正在接受常规药物治疗的特发性帕金森病患者，采用双盲法将其随机分为安慰剂组和迷迭香组。所有患者在饮用迷迭香茶或安慰剂（第 0 天）前和实验结束时（第 30 天）均接受了验证工具（UPDRSIII、NMSS 和 BDI）的临床评估。
治疗组在人口统计学和临床变量方面在基线时相似。在研究过程中，由于不遵医嘱和无法随访，有 9 名参与者退出。51 名参与者完成了研究。在 30 天的治疗完成后，迷迭香茶的摄入并未降低 UPDRSIII 评分（[UPDRSIII D0 = 18.76 ± 8.58，D30 = 16.52 ± 7.96，p = 0.069]，p 值为 0.07）。然而，NMSS 和 BDI 评分均有显著改善（p < 0.0001 和 p < 0.0001）。评估患者的 UPDRSIII、NMSS 和 BDI 评分均未反映出安慰剂组有任何改善。在研究过程中未发现任何不良反应。
这些发现表明，与常规治疗联合饮用迷迭香茶可改善帕金森病患者的抑郁和非运动症状。运动症状的改善可能需要更长的治疗周期。然而，需要更多的研究，包括更多的参与者和持续时间超过 1 个月，以证明这些发现。
